positive
Recently
Biotech firm BillionToOne raises $273 m in U.S. IPO amid market rebound
BillionToOne raised $273 m in a U.
On 6 November 2025, U.S.-based molecular diagnostics company BillionToOne raised $273.1 million in its initial public offering, pricing at $60 per share, above its previously marketed range of $49–$55. The listing values the company at about $2.64 billion and comes as the U.S. IPO market shows signs of revival after a lull. Market watchers view the deal as a potential lead for other life-sciences companies considering public listings.